172921-32-3 Usage
General Description
2,5-difluoro-4-nitrobenzonitrile is a chemical compound with the molecular formula C7H2F2N2O2. It is a nitrobenzonitrile derivative, which means it contains a nitro group (-NO2) and a benzonitrile group (-C≡N) in its molecular structure. 2,5-difluoro-4-nitrobenzonitrile is used in organic synthesis and as a building block for the production of other chemicals. It is also known for its potential biological and pharmacological activities, and has been studied for its potential use in medicinal chemistry. Due to its nitro and fluorine substituents, 2,5-difluoro-4-nitrobenzonitrile may exhibit unique reactivity and properties, making it a valuable compound for various industrial and scientific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 172921-32-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,9,2 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 172921-32:
(8*1)+(7*7)+(6*2)+(5*9)+(4*2)+(3*1)+(2*3)+(1*2)=133
133 % 10 = 3
So 172921-32-3 is a valid CAS Registry Number.
172921-32-3Relevant articles and documents
A 2, 5 - difluoro -4 - nitro benzoic acid (by machine translation)
-
, (2019/03/08)
The invention discloses a 2, 5 - difluoro - 4 - nitro-benzoic acid industrial preparation method. The 2, 5 - difluoro - 4 - nitro-benzoic acid industrial preparation method, the initial raw materials to the difluoro, through the bromo, nitration, carbonitriding, the hydrolysis of the four-step reaction synthesis of 2, 5 - difluoro - 4 - nitro-benzoic acid. The got in the course of 2, 5 - difluoro - 4 - nitrobenzoic acid as white powdery solid, purity 98.5%, each step the raw material conversion rate respectively reaches 100%, the total yield of the whole process 44.6%. (by machine translation)
TRPV4 ANTAGONISTS
-
Page/Page column 44-45, (2013/02/28)
The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
